Ishibashi Masumi 石橋ますみ

… Alternative Names

ISHIBASHI Masumi 石橋ますみ

Less

Researcher Number	20821383
Other IDs
Affiliation (Current)	2025: 東北大学, 大学病院, 講師
Affiliation (based on the past Project Information) *help	2024: 東北大学, 大学病院, 講師 2020 – 2023: 東北大学, 大学病院, 助教 2019: 東北大学, 医学系研究科, 大学院非常勤講師 2019: 東北大学, 医学系研究科, 非常勤講師 2018: 東北大学, 大学病院, 助教
Review Section/Research Field	Principal Investigator Basic Section 50010:Tumor biology-related / 0901:Oncology and related fields Except Principal Investigator Basic Section 56040:Obstetrics and gynecology-related
Keywords	Principal Investigator TIE-1 / PROTAC / 薬剤耐性 / ヌクレオチド除去修復 / DNA損傷修復機構 / 卵巣癌 / PI3K / DNA損傷修復 / シスプラチン / DNA repair / chemo-resistance / cisplatin … More Except Principal Investigator … More 卵巣癌 / セラミド / ネクロプトーシス / 循環腫瘍DNA / メタボローム / がんゲノム解析 / 婦人科がん / メタボロミクス / オミックス / バイオマーカー / 薬剤耐性 Less

上皮性卵巣癌におけるネクロプトーシスの臨床的意義と治療標的としての可能性
- Principal Investigator
  
  橋本千明
- Project Period (FY)
  2024 – 2026
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 56040:Obstetrics and gynecology-related
- Research Institution
  Tohoku University
卵巣癌の新規治療標的 TIE-1 に対する PROTAC を用いた阻害剤の開発Principal Investigator
- Principal Investigator
  
  石橋ますみ
- Project Period (FY)
  2022 – 2024
- Research Category
  
  Grant-in-Aid for Early-Career Scientists
- Review Section
  
  Basic Section 50010:Tumor biology-related
- Research Institution
  Tohoku University
Comprehensive genomic and transcriptome analyses to clarify molecular mechanisms contributing to chemoresistance in gynecologic cancer
- Principal Investigator
  
  YAEGASHI Nobuo
- Project Period (FY)
  2019 – 2021
- Research Category
  
  Grant-in-Aid for Scientific Research (B)
- Review Section
  
  Basic Section 56040:Obstetrics and gynecology-related
- Research Institution
  Tohoku University
The molecular mechanism of Tyrosine kinase receptor TIE-1 as the therapeutic target for ovarian cancer.Principal Investigator
- Principal Investigator
  
  ISHIBASHI Masumi
- Project Period (FY)
  2018 – 2019
- Research Category
  
  Grant-in-Aid for Research Activity Start-up
- Review Section
  
  0901:Oncology and related fields
- Research Institution
  Tohoku University

All 2022 2021

All Journal Article Presentation

[Journal Article] MicroRNA-152 Regulates Endometrial Serous Carcinoma Cell Motility by Suppressing Matrix Metalloproteinase 10 Expression2022
- Author(s)
  Shigeta S, Watanabe Y, Suzuki F, Nagase S, Shibuya Y, Ishibashi M, Nagai T, Shiga N, Toyoshima M, Tokunaga H, Shimada M, Yaegashi N.
- Journal Title
  
  Tohoku J. Exp. Med.
  
  Volume: 256 Issue: 3 Pages: 249-258
- DOI
  10.1620/tjem.256.249
- ISSN
  0040-8727, 1349-3329
- Language
  English
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-19H03795
[Journal Article] A Single Arm Prospective Pilot Study Examining the Efficacy and Safety of Bevacizumab Single Maintenance Therapy Following Platinum-Based Chemotherapy in Patients with Advanced or Recurrent Cervical Cancer.2021
- Author(s)
  Toyoshima M, Shimada M, Sasaki S, Ishibashi M, Shigeta S, Tsuji K, Nagai T, Tokunaga H, Niikura H, Yaegashi N.
- Journal Title
  
  Tohoku J Exp Med.
  
  Volume: 254(3) Issue: 3 Pages: 145-153
- DOI
  10.1620/tjem.254.145
- NAID
  130008061848
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-19H03795, KAKENHI-PROJECT-17K11265
[Journal Article] CHD4 regulates platinum sensitivity through MDR1 expression in ovarian cancer: A potential role of CHD4 inhibition as a combination therapy with platinum agents.2021
- Author(s)
  Oyama Y, Shigeta S, Tokunaga H, Tsuji K, Ishibashi M, Shibuya Y, Shimada M, Yasuda J, Yaegashi N.
- Journal Title
  
  PLoS One.
  
  Volume: 16(6) Issue: 6 Pages: 0251079-0251079
- DOI
  10.1371/journal.pone.0251079
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-19H03795, KAKENHI-PROJECT-19K09747, KAKENHI-PROJECT-21K09531, KAKENHI-PROJECT-20K18211
[Presentation] Development of TIE-1 target therapy for ovarian cancer2022
- Author(s)
  石橋　ますみ
- Organizer
  第７４回日本産科婦人科学会学術講演会
- Data Source
  KAKENHI-PROJECT-22K15536
[Presentation] チロシンキナーゼ受容体型蛋白TIE-1の卵巣癌に対する抗腫瘍効果の検討2022
- Author(s)
  石橋　ますみ
- Organizer
  第６４回日本婦人科腫瘍学会学術講演会
- Data Source
  KAKENHI-PROJECT-22K15536

1. YAEGASHI Nobuo (00241597)

# of Collaborated Projects: 1 results

# of Collaborated Products: 2 results
2. 安田純 (00281684)

# of Collaborated Projects: 1 results

# of Collaborated Products: 1 results
3. 島田宗昭 (40362892)

# of Collaborated Projects: 1 results

# of Collaborated Products: 2 results
4. 徳永英樹 (30595559)

# of Collaborated Projects: 1 results

# of Collaborated Products: 2 results
5. 橋本千明 (50821625)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
6. 重田昌吾 (90842633)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
7. 北谷和之 (40539235)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results

Ishibashi Masumi 石橋 ますみ

ISHIBASHI Masumi 石橋 ますみ

Research Projects

Research Products

Co-Researchers

上皮性卵巣癌におけるネクロプトーシスの臨床的意義と治療標的としての可能性

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

卵巣癌の新規治療標的 TIE-1 に対する PROTAC を用いた阻害剤の開発Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Comprehensive genomic and transcriptome analyses to clarify molecular mechanisms contributing to chemoresistance in gynecologic cancer

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

The molecular mechanism of Tyrosine kinase receptor TIE-1 as the therapeutic target for ovarian cancer.Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

[Journal Article] MicroRNA-152 Regulates Endometrial Serous Carcinoma Cell Motility by Suppressing Matrix Metalloproteinase 10 Expression2022

Author(s)

Journal Title

DOI

ISSN

Language

Data Source

[Journal Article] A Single Arm Prospective Pilot Study Examining the Efficacy and Safety of Bevacizumab Single Maintenance Therapy Following Platinum-Based Chemotherapy in Patients with Advanced or Recurrent Cervical Cancer.2021

Author(s)

Journal Title

DOI

NAID

Data Source

[Journal Article] CHD4 regulates platinum sensitivity through MDR1 expression in ovarian cancer: A potential role of CHD4 inhibition as a combination therapy with platinum agents.2021

Author(s)

Journal Title

DOI

Data Source

[Presentation] Development of TIE-1 target therapy for ovarian cancer2022

Author(s)

Organizer

Data Source

[Presentation] チロシンキナーゼ受容体型蛋白TIE-1の卵巣癌に対する抗腫瘍効果の検討2022

Author(s)

Organizer

Data Source

Ishibashi Masumi 石橋ますみ

ISHIBASHI Masumi 石橋ますみ